Automated Author Profile
Coleen Cunningham

Current S-Index

0.8

Sum of Dataset Indices for all datasets

Average Dataset Index per Dataset

0.4

Average Dataset Index per dataset

Total Datasets

Total datasets for this author

Average FAIR Score

15.4%

Average FAIR Score per dataset

Total Citations

Total citations to the author's datasets

Total Mentions

Total mentions of the author's datasets

S-Index Interpretation

The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.

What it means:

A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
It provides a single number to track your research data impact over time

Current S-Index: 0.8 (sum of 2 datasets Dataset Index scores)

More information here.

S-Index Over Time

Cumulative Citations Over Time

Cumulative Mentions Over Time

Datasets

Hepatitis B Vaccination in Youth at Adolescent Trials Network Sites: Effectiveness of Two Strategies and Evaluation of Tools to be Used in Future HIV Prevention Trials (Version: V1)

A randomized, single-blinded trial evaluating two licensed vaccine products, Recombivax and Twinrix, given in a two-dose schedule to youth at risk for HIV and hepatitis B infection. Primary objectives were to determine immunogenicity of the products in the study population and to determine safety and tolerability of the vaccines given in the two regimens.

Authors

Coleen Cunningham ;
Patricia Flynn

0 Citations0 Mentions15% FAIR0.4 Dataset Index

10.57982/66ds-7s05January 2018

A Randomized, Open-Label Trial of Three Hepatitis B Vaccination Schemas in HIV-Positive Youth (Version: V1)

Suboptimal response to hepatitis B vaccination in HIV-positive adults and children has been well documented in the literature. This Phase 4 trial compared the immune system response to 3 hepatitis B vaccine regimens in HIV-positive adolescents 12 through 24 years of age. The three vaccination schemas were the standard adult dosing of hepatitis B virus (HBV)-only vaccine (Engerix 20mcg), the increased adult dosing of HBV-only vaccine (Engerix 40 mcg), and the standard adult dosing of combined HBV/hepatitis A virus vaccine (Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg), all at Entry, Week 4, and Week 24. Primary sero-reponses were evaluated at Week 28, and primary non-responders (antibody response of < 10 IU/ml) were provided with a booster vaccine using the increased-dose Engerix-B vaccine at Week 48.